HAVCR2 and acute myeloid leukemia: Similarly, Williams et al. (38) reported a trend toward a higher frequency of CD8+PD-1+TIM3+ T cells and CD8+PD-1+LAG3+ T cells in the bone marrow (BM) of AML patients with relapse.